Macquarie Group LTD Spring Works Therapeutics, Inc. Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 53,381 shares of SWTX stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

53,381

Previous 44,162 20.88%

Holding current value

$2.08 Million

Previous $1.66 Million 2.83%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$32.04 - $42.76 $295,376 - $394,204	9,219 Added 20.88%	53,381 $1.71 Million
Q2 2024 Aug 09, 2024	BUY	$36.06 - $47.62 $206,515 - $272,719	5,727 Added 14.9%	44,162 $1.66 Million
Q1 2024 May 14, 2024	SELL	$36.5 - $52.5 $269,917 - $388,237	-7,395 Reduced 16.14%	38,435 $1.89 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $126,235 - $248,204	6,665 Added 17.02%	45,830 $1.67 Million
Q3 2023 Nov 14, 2023	BUY	$23.12 - $31.38 $17,663 - $23,974	764 Added 1.99%	39,165 $905,000
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $135,797 - $191,876	5,866 Added 18.03%	38,401 $1.01 Million
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $9,813 - $13,381	-393 Reduced 1.19%	32,535 $837,000
Q4 2022 Feb 21, 2023	BUY	$21.73 - $28.72 $712,570 - $941,786	32,792 Added 24111.76%	32,928 $856,000
Q3 2022 Nov 14, 2022	SELL	$24.1 - $39.66 $6,000 - $9,875	-249 Reduced 64.68%	136 $11,000
Q1 2021 May 14, 2021	SELL	$65.1 - $93.59 $7,681 - $11,043	-118 Reduced 23.46%	385 $28,000
Q2 2020 Aug 11, 2020	BUY	$22.98 - $48.57 $11,558 - $24,430	503 New	503 $21,000

Others Institutions Holding SWTX

# of Institutions

238

Shares Held

69.8M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Spring Works Therapeutics, Inc. Transaction History